Nanoparticle-mediated delivery of PD-L1 inhibitor enhances γδ T cell immunotherapy against metastatic ovarian cancer cells
Authors:
Preprint
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) have only shown limited efficacy for patients with ovarian cancer (OC), partly due to the immune suppressive tumour microenvironment (TME) and platelet cloaking of the cancer cells. We tested a nanomedicine strategy to enhance γδ T cell immunotherapy by conjugating the PD-L1 inhibitor (BMS202) to nanodiamonds (NDs). Methods: Patient-derived ascites cells were exposed to activated platelets to model platelet cloaking and the immunosuppressive phenotype in metastatic OC. ND/BMS202 nanocomplexes were then applied to platelet-conditioned OC cells and co-cultured with expanded γδ T cells. Cytotoxicity and immune activation were assessed by quantifying Granzyme B, CD107a, γ-H2AX, cleaved caspase-3, and cleaved caspase-8. Results: ND-mediated delivery of BMS202 significantly enhanced γδ T cell-mediated killing of platelet cloaked OC cells in a dose-dependent manner, with greater efficacy than free BMS202 This enhanced cytotoxicity was supported by increased degranulation (CD107a), Granzyme B release, tumour cell apoptosis (caspase cleavage) and DNA damage (γ-H2AX staining). Conclusions: ND-based delivery of the PD-L1 inhibitor (BMS202) enhances γδ T cell-mediated killing of platelet-cloaked metastatic OC cells. While our data support enhanced γδ T cell cytotoxicity following BMS202 delivery, direct evidence of PD-L1 target engagement or PD-1/PD-L1 binding inhibition was not demonstrated in this study. These findings nonetheless justify further validation in patient-derived organoid models to optimize this γδ T cell-based combination immunotherapy and advance its development as a precision therapeutic strategy for metastatic OC.Keywords
This publication has 78 references indexed in Scilit:
- Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanomaJournal of Colloid and Interface Science, 2022
- PARP1: Structural insights and pharmacological targets for inhibitionDNA Repair, 2021
- Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancerArchives of Gynecology and Obstetrics, 2020
- Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumorsJournal of Leukocyte Biology, 2019
- Environmental and toxicological assessment of nanodiamond-like materials derived from carbonaceous aerosolsScience of The Total Environment, 2019
- Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical OncologyClinical and Translational Oncology, 2017
- PRRX1 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancerMedical Oncology, 2014
- Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytesCancer Immunology, Immunotherapy, 2011
- Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigensEuropean Journal of Immunology, 2010
- Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progressionClinical & Experimental Metastasis, 2008